SDZNY Quote, Financials, Valuation and Earnings

Alcon has a net margin of -39.83% compared to Sandoz Group AG's net margin of 11.35%. Sandoz Group AG's return on equity of -- beat Alcon's return on equity of 4.85%.

Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Alcon has an analysts' consensus of $106.65 which suggests that it could grow by 10.98%. Given that Alcon has higher upside potential than Sandoz Group AG, analysts believe Alcon is more attractive than Sandoz Group AG.

Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alcon has a beta of 1.058, suggesting its more volatile than the S&P 500 by 5.816%.

Sandoz Group AG has a quarterly dividend of $0.67 per share corresponding to a yield of 1.52%. Alcon offers a yield of 0.28% to investors and pays a quarterly dividend of $0.26 per share. Sandoz Group AG pays -- of its earnings as a dividend. Alcon pays out 12.77% of its earnings as a dividend. Alcon's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sandoz Group AG quarterly revenues are $74.4M, which are smaller than Alcon quarterly revenues of $2.5B. Sandoz Group AG's net income of -$29.6M is lower than Alcon's net income of $284M. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while Alcon's PE ratio is 46.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 1.85x versus 4.82x for Alcon. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of -39.83% compared to Sandoz Group AG's net margin of -106.6%. Sandoz Group AG's return on equity of -- beat CRISPR Therapeutics AG's return on equity of -18.65%.

Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.00 which suggests that it could grow by 136.5%. Given that CRISPR Therapeutics AG has higher upside potential than Sandoz Group AG, analysts believe CRISPR Therapeutics AG is more attractive than Sandoz Group AG.

Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.877, suggesting its more volatile than the S&P 500 by 87.729%.

Sandoz Group AG has a quarterly dividend of $0.67 per share corresponding to a yield of 1.52%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

Sandoz Group AG quarterly revenues are $74.4M, which are larger than CRISPR Therapeutics AG quarterly revenues of $35M. Sandoz Group AG's net income of -$29.6M is higher than CRISPR Therapeutics AG's net income of -$37.3M. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 1.85x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -39.83% compared to Sandoz Group AG's net margin of 26.48%. Sandoz Group AG's return on equity of -- beat Novartis AG's return on equity of 30.96%.

Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Novartis AG has an analysts' consensus of $112.37 which suggests that it could grow by 0.6%. Given that Novartis AG has higher upside potential than Sandoz Group AG, analysts believe Novartis AG is more attractive than Sandoz Group AG.

Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.726%.

Sandoz Group AG has a quarterly dividend of $0.67 per share corresponding to a yield of 1.52%. Novartis AG offers a yield of 3.58% to investors and pays a quarterly dividend of $3.99 per share. Sandoz Group AG pays -- of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sandoz Group AG quarterly revenues are $74.4M, which are smaller than Novartis AG quarterly revenues of $13.6B. Sandoz Group AG's net income of -$29.6M is lower than Novartis AG's net income of $3.6B. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while Novartis AG's PE ratio is 17.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 1.85x versus 4.23x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of -39.83% compared to Sandoz Group AG's net margin of --. Sandoz Group AG's return on equity of -- beat Roche Holding AG's return on equity of 23.8%.

Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Roche Holding AG has an analysts' consensus of $46.42 which suggests that it could grow by 15.09%. Given that Roche Holding AG has higher upside potential than Sandoz Group AG, analysts believe Roche Holding AG is more attractive than Sandoz Group AG.

Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.468, suggesting its less volatile than the S&P 500 by 53.23%.

Sandoz Group AG has a quarterly dividend of $0.67 per share corresponding to a yield of 1.52%. Roche Holding AG offers a yield of 3.38% to investors and pays a quarterly dividend of $1.36 per share. Sandoz Group AG pays -- of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sandoz Group AG quarterly revenues are $74.4M, which are larger than Roche Holding AG quarterly revenues of --. Sandoz Group AG's net income of -$29.6M is higher than Roche Holding AG's net income of --. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while Roche Holding AG's PE ratio is 28.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 1.85x versus 3.69x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.